HANNAH THROGMORTON: Open Payments
NPI 1336920206 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 79 payments from 13 companies in 2025. Trend: 2023 $403 · 2024 $1,633 · 2025 $1,514
Food & beverage: $1,514
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $309 |
| Alkermes, Inc. | 10 | $188 |
| Otsuka America Pharmaceutical, Inc. | 15 | $187 |
| E.R. Squibb & Sons, L.L.C. | 4 | $169 |
| Tris Pharma Inc | 6 | $129 |
| Teva Pharmaceuticals USA, Inc. | 2 | $125 |
| Neos Therapeutics, LP | 5 | $87 |
| Corium, LLC | 3 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
Products named: VRAYLAR, REXULTI, COBENFY, LYBALVI, UZEDY, Onyda XR, Adzenys XR-ODT, Azstarys.
Industry payments across TX — which companies pay providers there.
